© 2021 All rights reserved, FreshLeaf Analytics
FRESHLEAF ANALYTICS Q1 2020
It seems possible that CBD will become available for behind the counter pharmacy sales. But the path to market will be challenging for many cannabis companies. December 2019 saw an annualised product sales run rate of nearly $50M. FreshLeaf expects that by December 2020 this will have nearly tripled to around $150M.